SciSparc Ltd

SciSparc Ltd. is a clinical stage pharmaceutical company, which focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The firm initiated two internal drug development programs based on repurposing an FDA approved synthetic cannabinoid (dronabinol): Joint Pharma developing THX-TS01 targeted to the treatment of TS and Brain Bright Pharma developing THX-ULD01 targeted to the high value and under-served market of MCIs. Its products include SCI-110, SCI-210, SCI-160, and CannAmide. The company was founded on August 23, 2004 and is headquartered in Tel Aviv, Israel.

Earnings data Q4 2023

The non- clinical study was conducted at The Chaim Sheba Medical Center in Israel

SciSparc Announces Positive Study Results with SCI-210, a Cannabidiol-Based Treatment for Epilepsy

The new line of products will be in the fields of quality health and lifestyle products such as nutritional and dietary supplements for various purposes

SciSparc Enters Into Letter of Intent with an E-commerce Company to Establish a Joint Venture to Market and Develop a New Product Line

Tel-Aviv, Nov. 07, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company” or “SciSparc”), today announced positive interim results from its Phase IIa trial of SCI-110 in patients with Alzheimer's Disease (“AD”) and agitation. Agitation manifests in the course of AD progression in almost all affected patients, increasing patients' suffering and burden of care.

SciSparc Announced Positive Interim Results Meeting Primary Endpoints at Phase IIa Study in Alzheimer's Disease Patients with Agitation

Agrify

TAL Education Group

Check these recommendations for buying penny stocks The post Buying Penny Stocks? 3 Analyst Recommendations to Use appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Buying Penny Stocks? 3 Analyst Recommendations to Use

Alset EHome International

Ainos Inc

Which penny stocks are you watching right now? The post Buying Penny Stocks This Week?

Buying Penny Stocks This Week? What You Need to Know

Wellution™ offers dozens of products including natural supplements, creams, gels and hemp-based products on Amazon.com Marketplace

SciSparc Completes the Acquisition of Wellution™, Top Seller of American Food Supplements and Cosmetics Brand on Amazon, for $20 million

TEL AVIV, Israel, Sept. 22, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that Clearmind Medicine Inc. (“Clearmind”) (CSE: CMND), (OTC: CMNDF), (FSE: CWY0), has filed a provisional patent application related to metabolic syndromes including obesity, regarding the Company's collaboration with Clearmind.

SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields 3rd Patent Application for the Treating of Obesity and Metabolic Syndromes

AMTD International Inc

Akerna Corp

Looking for penny stocks to buy today? 3 for your watchlist right now The post Top Penny Stocks to Buy Right Now?

Top Penny Stocks to Buy Right Now? 3 for Your Mid-September List

SciSparc Enters Agreement to Acquire Wellution™, Top Seller of American Food Supplements and Cosmetics Brand on Amazon, for $20 million

Bright Minds Biosciences

Seelos Therapeutics

Psychedelics stocks, like Seelos Therapeutics (NASDAQ: SEEL ), Scisparc (NASDAQ: SPRC ) and Bright Minds Biosciences (NASDAQ: DRUG ), are taking off today. This morning, it was announced that the Michael J.

Why Are Psychedelics Stocks Up Today?

Results indicate significant decrease in cocaine craving in a sub-group that received the treatment

SciSparc Ltd. Announces Additional Positive Results for the Cocaine Addiction Treatment of its Psychedelic-based Pharma Collaboration with Clearmind Medicine Inc.

The pre-funded warrants were issued as part of the $10 million private placement from June 2022

Scisparc Announces the Full Exercise of Pre-Funded Warrants

The Company has signed an escrow agreement following the signing of a non-binding letter of intent and will be deposit a $1 .0 million as an initial intention to enter into a definitive acquisition agreement

SciSparc will Deposit $1 million in Escrow for its Intention to Enter Into an Agreement to Acquire American Food Supplements and Cosmetics Brand

The Letter of Intent contemplates the purchasing of a brand, trademark and Amazon.com seller account, a management agreement, a U.S. distribution agreement and an option to expand to new territories

SciSparc Signs a Non- Binding Letter of Intent to Acquire American Food Supplements and Cosmetics Brand in Approximately $20 Million Deal

Patent extends protection for SciSparc's novel compounds and methods a lready granted i n the U . S . , Australia a nd Japan

SciSparc Issued Israeli Patent for its Core Technology for Treating Central Nervous Systems Disorders

The trial's objectives are to evaluate the safety, tolerability and efficacy of SciSparc's SCI-210 in children and adolescents with ASD

SciSparc Announces Israeli Ministry of Health Approval to Conduct its Clinical Trial in Autism Spectrum Disorder

The addition of a U . S . site will allow SciSparc to accelerate trial recruitment and further development of novel treatments for patients in need

SciSparc Signs Clinical Trial Agreement with Yale University to Conduct its Phase IIb Trial in Tourette Syndrome

TEL AVIV, Israel, July 08, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced it has started the process of preparing for an Investigational New Drug Application (“IND”) with the U.S. Food and Drug Administration (“FDA”) for its Phase IIb clinical trial for SCI-110 in patients suffering from Tourette Syndrome ("TS").

SciSparc Announces Expanding its Clinical Operations to Include a U.S. Site Towards its Phase IIb Trial with its Proprietary SCI-110 for the Treatment of Tourette Syndrome

The new facility will serve the JV 's development of potential cancer drugs

SciSparc's JV MitoCareX Bio Launches its Advanced New Laboratory Facility

NEW YORK, NY / ACCESSWIRE / July 7, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid cap publicly traded companies recently issued a new C-Level interview with SciSparc Ltd. Mark Roberts, Senior Editor at Traders News Source had the opportunity to conduct the interview featuring Oz Adler Chief Executive Officer at SciSparc.

Traders News Source Interviews Oz Adler Chief Executive Officer at SciSparc Ltd.

TEL AVIV, Israel, June 29, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that it has successfully completed the development of its top-tier drug candidate SCI-110 to be used in its upcoming multinational, multicenter, Phase IIb study for Tourette Syndrome ("TS").

SciSparc Successfully Completed The Development of its Proprietary Drug Candidate SCI-110 for its Upcoming Phase IIb Study In Tourette Syndrome

The Soroka University Ethics Committee Approval Received to Conduct a Clinical trial with SciSparc's Proprietary SCI-210 Treatment

SciSparc Announces Ethics Committee Approval to Conduct its Clinical Trial in Autism Spectrum Disorder

JV Targets Potential Drugs for Cancers and Infectious Diseases

SciSparc Reinforces its New JV for Targeting Discovery with a Global Expert in the Field of Mitochondrial Transport Proteins

TEL AVIV, Israel, June 09, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today announced that the Company's board of directors resolved to initiate a process to review potential strategic transactions with the goal of maximizing shareholder value.

SciSparc's Board of Directors Provides Strategic Decision

NEW YORK, NY / ACCESSWIRE / June 2, 2022 / Aegis Capital Corp. acted as Exclusive Placement Agent on a $10 Million Private Placement Priced At-the-Market for SciSparc Ltd. (NASDAQ:SPRC).

News for SciSparc Ltd Stock (SPRC)